Demo portfolio

A fortress balance sheet

The company's balance sheet is exceptional.

Deep value

Our DCF model says ABBV trades at a 28% discount to intrinsic value.

A strong moat

AbbVie’s moat is primarily rooted in patents, regulatory exclusivity, clinical data, brands, and specialized commercialization capabilities. Skyrizi and Rinvoq have differentiated efficacy, durable outcomes, broad approved indications, and entrenched physician/payer positioning; Skyrizi has U.S. regulatory data protection through 2031 and additional patents extending into the mid-2030s and later. High adjusted gross margins (83.6% in Q1 2026; above-84% full-year guidance) and an expected 47.5% adjusted operating margin demonstrate scale and the economics of a branded-biopharma portfolio, although these are not a structural low-cost advantage in the traditional sense. Switching costs are meaningful because changing therapies can disrupt disease control, require new authorization and monitoring processes, and carries clinical uncertainty, while network effects are limited because pharmaceutical products do not become intrinsically more valuable with additional users. The reported 3.1% TTM ROIC and zero stated TTM FCF warrant caution, and substantial intangible assets, goodwill, and debt reflect the capital intensity and acquisition dependence of the business.

Watch

The key threat is patent expiration and biosimilar/generic competition, alongside increasingly crowded immunology markets and persistent payer-driven rebate and price pressure; management expects low-single-digit pricing erosion in immunology. Competition, regulatory pricing controls, clinical trial or approval setbacks, and execution risk in replacing mature-product declines could reduce the durability of returns.

Strong growth

AbbVie reported first-quarter revenue growth of 12.4% and adjusted EPS of $2.65, exceeding the guidance midpoint, supported by strong immunology performance; Skyrizi sales reached $4.5 billion and grew 29.2% operationally. Management raised full-year EPS guidance and continues to forecast an adjusted operating margin of about 47.5%, while identifying upside to consensus revenue and significant additional runway for Skyrizi and Rinvoq beyond 2031 expectations. The growth platform is broadening through neuroscience, oncology business development, and pipeline milestones including ABBV-295 obesity data and an earlier expected temab-A regulatory submission. Cash generation remains substantial at $18.21 billion of TTM free cash flow, although the historical FCF CAGR of negative 9.8% tempers the otherwise strong operating momentum.

Watch

Growth depends heavily on sustained execution and competitive durability for Skyrizi and Rinvoq, including against emerging oral and biologic alternatives, while aesthetics demand appears more economically sensitive. SEC filings highlight material clinical, regulatory, manufacturing, reimbursement, pricing and IRA-related risks; pipeline assets remain subject to uncertain trial outcomes and approval timing.